NTRK2 and Alzheimer disease: We have previously shown that several independent antibodies raised against phosphorylated tyrosines Y705/706 or Y816 within the intracellular domain of TrkB all show increased phospho-TrkB levels after acute and chronic AD treatment [13], [15], while no increase is detected with antibodies against the shc binding site at pY515.